Status:
RECRUITING
Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Elisabeth-TweeSteden Ziekenhuis
Amphia Hospital
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
45+ years
Phase:
NA
Brief Summary
Rationale: Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer (EC). Therefore, a Bayesian network model called ENDORISK was developed ...
Eligibility Criteria
Inclusion
- Diagnosed with early stage (FIGO stage I-II) endometrial carcinoma (every grade permitted)
- Eligible for primary surgical treatment (neo-adjuvant therapy is permitted)
Exclusion
- Unable to give informed consent
- No understanding of Dutch or English language
- Rare types of endometrial cancer, such as endometrial stroma cell sarcoma
Key Trial Info
Start Date :
October 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 16 2032
Estimated Enrollment :
735 Patients enrolled
Trial Details
Trial ID
NCT07200466
Start Date
October 23 2025
End Date
October 16 2032
Last Update
December 17 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Rijnstate
Arnhem, Gelderland, Netherlands
2
Slingeland Hospital
Doetinchem, Gelderland, Netherlands
3
Gelderse Vallei
Ede, Gelderland, Netherlands
4
Radboudumc
Nijmegen, Gelderland, Netherlands, 6525GA